Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib.
Ohio State University, Columbus, OH.
John C
JC
Byrd
Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom.
Peter
P
Hillmen
Pharmacyclics, Sunnyvale, CA.
Danelle F
DF
James
D000818:Animals; D001281:Atrial Fibrillation / Q000378:metabolism*; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D011720:Pyrazoles / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D015398:Signal Transduction / Q000187:drug effects*
D011720:Pyrazoles; D011743:Pyrimidines; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt